Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciclosporin, quantity: 25 mg - capsule, soft - excipient ingredients: gelatin; titanium dioxide; lecithin; peg-40 hydrogenated castor oil; purified water; iron oxide black; sorbitan oleate; polysorbate 20; ethyl lactate; tricaprin; glycerol - ciclosporin is indicated: ? as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. ? for induction and/or maintenance of remission in the nephrotic syndrome. ciclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see section 4.4 special warnings and precautions for use). ? for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. ? in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. ? for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.,careful monitoring of all ciclosporin-treated patients is mandatory. ciclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see section 4.4 special warnings and precautions for use).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciclosporin, quantity: 50 mg - capsule, soft - excipient ingredients: polysorbate 20; lecithin; gelatin; glycerol; peg-40 hydrogenated castor oil; titanium dioxide; iron oxide black; tricaprin; sorbitan oleate; ethyl lactate; purified water - ciclosporin is indicated: ? as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. ? for induction and/or maintenance of remission in the nephrotic syndrome. ciclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see section 4.4 special warnings and precautions for use). ? for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. ? in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. ? for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.,careful monitoring of all ciclosporin-treated patients is mandatory. ciclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see section 4.4 special warnings and precautions for use).

Israel - English - Ministry of Health

novartis israel ltd - ciclosporin - capsules - ciclosporin 100 mg - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - ciclosporin - concentrate for oral solution - 100 mg/ml - calcineurin inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - ciclosporin - concentrate for oral solution - 100 mg/ml - calcineurin inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

ceva santé animale - ciclosporin - oral solution - 100 mg/ml - ciclosporin - canine - miscellaneous

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - ciclosporin - capsule, soft - 100 milligram(s) - calcineurin inhibitors; ciclosporin

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - ciclosporin - concentrate for oral solution - 100 milligram(s)/millilitre - calcineurin inhibitors; ciclosporin

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - ciclosporin - capsule, soft - 100 milligram(s) - calcineurin inhibitors; ciclosporin

New Zealand - English - Medsafe (Medicines Safety Authority)

hexal new zealand pty limited (ceased trading 31.12.2006) - ciclosporin 100 mg/ml - oral solution - 100 mg/ml - active: ciclosporin 100 mg/ml excipient: ethanol macrogol 400 polyethylene glycol hydrogenated castor oil tocofersolan